Phase I study of MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid tumors, as monotherapy or in combination with pembrolizumab

被引：0
|
作者：
Kyi, Chrisann
Van Dongen, Marloes
Rottey, Sylvie
Bermejo, Ignacio Melero
Mittag, Diana
Gouveia, Dane
Bol, Kees
Yan, Chris
Joe, Andrew K.
Laus, Gianluca
Moreno, Victor
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Netherlands Canc Inst, Antoni Van Leeuwenhoek, Amsterdam, Netherlands
[3] Ghent Univ Hosp, Ghent, Belgium
[4] Univ Navarra Clin, Pamplona, Spain
[5] Merus NV, Utrecht, Netherlands
[6] Univ Hosp Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2520
引用
收藏
页数：1
相关论文
共 50 条
  • [21] FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, Exhibits Low Toxicity and Antitumor Activity in Colorectal Cancer Models
    Lakins, Matthew A.
    Koers, Alexander
    Giambalvo, Raffaella
    Munoz-Olaya, Jose
    Hughes, Robert
    Goodman, Emma
    Marshall, Sylwia
    Wollerton, Francisca
    Batey, Sarah
    Gliddon, Daniel
    Tuna, Mihriban
    Brewis, Neil
    CLINICAL CANCER RESEARCH, 2020, 26 (15) : 4154 - 4167
  • [22] GEN1046 (Bispecific Antibody Targeting PD-L1 and 4-1BB): Preclinical Characteristics and Phase 1 Results in Solid Tumors
    Kunkel, Maria
    Muik, Alexander
    Altintas, Isil
    Gieseke, Friederike
    Schodel, Kristina
    Diken, Mustafa
    Sette, Angelica
    Stanganello, Eliana
    Vascotto, Fulvia
    Breij, Esther
    Sasser, Kate
    Tureci, Ozlem
    Forssmann, Ulf
    Ahmadi, Tahamtan
    Sahin, Ugur
    CANCER SCIENCE, 2023, 114 : 1566 - 1566
  • [23] A phase Ia/b study of TIM-3/PD-L1 bispecific antibody in patients with advanced solid tumors.
    Hellmann, Matthew David
    Shimizu, Toshio
    Doi, Toshihiko
    Hodi, F. Stephen
    Rottey, Sylvie
    Aftimos, Philippe Georges
    Liu, Zhuqing Tina
    de Mendizabal, Nieves Velez
    Szpurka, Anna M.
    Piao, Yongzhe
    Vangerow, Burkhard
    Gandhi, Leena
    Leow, Ching Ching
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Combination of CEA TCB, a novel T -cell bispecific antibody for the treatment of solid tumors, with PD-L1 checkpoint blockade
    Bacac, Marina
    Fauti, Tanja
    Colombetti, Sara
    Fahrni, Linda
    Nicolini, Valeria
    Gerdes, Christian
    Saro, Jose
    Karanikas, Vaios
    Klein, Christian
    Umana, Pablo
    CANCER RESEARCH, 2016, 76
  • [25] Preliminary results from a phase I expansion study of ZG005, a bispecific antibody targeting TIGIT and PD-1, as monotherapy in patients with advanced solid tumors
    Qin, Shukui
    Cheng, Ying
    Wang, Qiming
    Cheng, Shuxia
    Chai, Xiaoli
    Wu, Lihua
    Yu, Yan
    Shi, Jianhua
    Li, Xiumin
    Fan, Lianlian
    Xia, Jin
    Huang, Yisheng
    Ji, Yinghua
    Zhuang, Zhixiang
    Yang, Lei
    Jiang, Ou
    Zheng, Qinhong
    Liao, Sihai
    Yi, Shanyong
    Ye, Huangyang
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [26] PHASE 1 STUDY OF AN ANTI-CD27 AGONIST AS MONOTHERAPY AND IN COMBINATION WITH PEMBROLIZUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
    Shapira-Frommer, Ronnie
    van Dongen, Marloes G. J.
    Dobrenkov, Konstantin
    Chartash, Elliot
    Liu, Fang
    Li, Claire
    Wnek, Richard
    Patel, Manish
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A2 - A2
  • [27] CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models
    Puigdelloses, Montserrat
    Garcia-Moure, Marc
    Labiano, Sara
    Laspidea, Virginia
    Gonzalez-Huarriz, Marisol
    Zalacain, Marta
    Marrodan, Lucia
    Martinez-Velez, Naiara
    De la Nava, Daniel
    Ausejo, Iker
    Hervas-Stubbs, Sandra
    Herrador, Guillermo
    Chen, ZhiHong
    Hambardzumyan, Dolores
    Patino Garcia, Ana
    Jiang, Hong
    Gomez-Manzano, Candelaria
    Fueyo, Juan
    Perez de Larraya, Jaime Gallego
    Alonso, Marta
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 (07)
  • [28] First-in-human study (FIH) of FS222, a next-generation tetravalent PD-L1/CD137 bispecific antibody: Safety, pharmacodynamics (PD), and antitumor activity in patients (pts) with advanced solid tumors including PD-1 refractory melanoma
    Garralda, Elena
    Oberoi, Arjun
    de Velasco, Guillermo
    Victoria, Ivan
    Pesantez, David
    Eguren Santamaria, Inaki
    Moreno, Victor
    Boni, Valentina
    Cervantes, Andres
    Gambardella, Valentina
    Ciuleanu, Tudor-Eliade
    Bergamino Sirven, Milana
    Rodriguez-Abreu, Delvys
    Alonso, Guzman
    Minea Gales, Laurentia
    Jones, Daniel
    Patki, Abhay
    Ataman, Ozlem
    Melero Bermejo, Ignacio
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [29] Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients with Advanced Refractory Solid Tumors
    Muik, Alexander
    Garralda, Elena
    Altintas, Isil
    Gieseke, Friederike
    Geva, Ravit
    Ben-Ami, Eytan
    Maurice-Dror, Corinne
    Calvo, Emiliano
    LoRusso, Patricia M.
    Alonso, Guzman
    Rodriguez-Ruiz, Maria E.
    Schoedel, Kristina B.
    Blum, Jordan M.
    Sanger, Bianca
    Salcedo, Theodora W.
    Burm, Saskia M.
    Stanganello, Eliana
    Verzijl, Dennis
    Vascotto, Fulvia
    Sette, Angelica
    Quinkhardt, Juliane
    Plantinga, Theo S.
    Toker, Aras
    van den Brink, Edward N.
    Fereshteh, Mark
    Diken, Mustafa
    Satijn, David
    Kreiter, Sebastian
    Breij, Esther C. W.
    Bajaj, Gaurav
    Lagkadinou, Eleni
    Sasser, Kate
    Tureci, Ozlem
    Forssmann, Ulf
    Ahmadi, Tahamtan
    Sahin, Ugur
    Jure-Kunkel, Maria
    Melero, Ignacio
    CANCER DISCOVERY, 2022, 12 (05) : 1248 - 1265
  • [30] Tumor-targeted T-cell activation via an investigational PD-L1 x CD137 bispecific molecule
    Berezhnoy, Alexey
    Huang, Ling
    Liu, Daorong
    DiChiara, Jennifer
    Li, Jonathan
    Smith, Douglas
    Rillema, Jill
    Ciccarone, Valentina
    Tamura, James
    Alderson, Ralph
    Diedrich, Gundo
    Bonvini, Ezio
    Moore, Paul
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
12345